Literature DB >> 29227847

The impact of histological subtype in developing both ovarian and endometrial cancer: A longstanding nationwide incidence study.

Catharina C van Niekerk1, Jos A A M van Dijck2, André L M Verbeek2.   

Abstract

OBJECTIVES: To estimate the incidence of ovarian cancer (OC) and endometrial cancer (EC) separately, as well as double cancers diagnosed in the same calendar year, and to relate the occurrences to histological subtype. STUDY
DESIGN: All cases of epithelial OC and EC diagnosed in the Netherlands in 1989-2009 were related to population data. Histologically specific associations were made using the ratio of observed and expected incidence numbers, calculated with age-specific incidence rates.
RESULTS: 25,489 OC and 32,729 EC were analyzed, and 649 OC/EC. Life-time risks for OC and EC were 1.8% and 2.4%. Among OC, adenocarcinoma (18%) and serous cancers (33%) were the most prevalent subtypes. In EC, adenocarcinoma (39%) and endometrioid cancer (37%) were highest, with hardly any serous cancers. The observed incidence of OC/EC was 50-fold higher than expected (95% CI, 46-54). For patients aged <55years, the O/E ratio was 274, for the elderly 32, both findings are significant. Of the 2345 OC endometrioid subtype, 294 had EC (12.5%), whereas 1.1 was expected. In EC patients, no particular histological subtype was distinguished with a highly elevated occurrence of OC. The 680 serous EC patients had 11 double cancers (1.6%), of which 8 with the ovarian serous subtype.
CONCLUSION: Strong relationships exist between malignancies in the ovary and a second primary malignancy in the endometrium, especially for the endometrioid subtype of ovarian cancer. Viewed from the endometrial site, no special subtype was noted, and the influence of endometrial serous adenocarcinoma in developing serous OC is not plausible.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Double tumors; Endometrioid and serous cancer; Endometrium cancer; Epidemiology; Ovarian cancer

Mesh:

Year:  2017        PMID: 29227847     DOI: 10.1016/j.ejogrb.2017.12.014

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

1.  β-Klotho inhibits CSF-1 secretion and delays the development of endometrial cancer.

Authors:  Fu Hua; Xiaogang Chen
Journal:  Cell Cycle       Date:  2022-06-28       Impact factor: 5.173

2.  Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study.

Authors:  Jiaqin Xu; Chen Huang; Zhenyu Wu; Huilin Xu; Jiong Li; Yuntao Chen; Ce Wang; Jingjing Zhu; Guoyou Qin; Xueying Zheng; Yongfu Yu
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

3.  Colony‑stimulating factor 1 receptor inhibition blocks macrophage infiltration and endometrial cancer cell proliferation.

Authors:  Fu Hua; Ye Tian; Yingchun Gao; Changhua Li; Xiaoping Liu
Journal:  Mol Med Rep       Date:  2019-02-18       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.